Biopharmaceuticals

AcelRx Pharmaceuticals, Inc.
Portola Valley, California
AcelRx Pharmaceuticals is an early stage company developing a novel drug delivery platform technology.
Contact: Guy P. Nohra
Achaogen, Inc.
South San Francisco, California,
Achaogen is a clinical stage biopharmaceutical company focused on the discovery and development of broad-spectrum antibiotics to treat multi-drug resistant bacterial infections.
Contact: Farah Champsi
Aegerion Pharmaceuticals, Inc.
Bridgewater, NJ
Aegerion Pharmaceuticals is a specialty pharmaceutical company focused on the development and commercialization of pharmaceutical products to treat cardiovascular and metabolic diseases.
Aerie Pharmaceuticals, Inc.
Research Triangle Park, NC
Aerie Pharmaceuticals is a privately held, clinical-stage biotechnology company dedicated to the discovery and development of novel treatments for glaucoma. Aerie’s internal research and development engine has generated an innovative glaucoma pipeline. In addition to AR-12286, the Company’s Rho-kinase (ROCK) inhibitor, the pipeline includes AR-13165, a novel product candidate with a dual mechanism of action that represents the first of a new proprietary class of glaucoma drugs. AR-13165 is currently in preclinical, IND-enabling studies. An ocular implant for long-term drug delivery is also being advanced towards the clinic. The Company is located in Bridgewater New Jersey and Research Triangle Park North Carolina
Alba Therapeutics Corp.
Baltimore, MD
Alba Therapeutics is focused on the development of novel therapeutics for the treatment of inflammatory and immune mediated diseases caused by the malfunction of tight junctions in body. Initial target diseases are Celiac Disease and Type I Diabetes. The Company is in Phase II studies.
Contact: Dan Janney
Allakos
San Mateo, CA
Allakos is a privately held, product-focused biotechnology company developing first-in-class antibody-based therapeutics to treat diseases in which dysregulation of the Th2 response plays a key role in pathology, including allergic disease, inflammation and diseases characterized by excess production of inflammatory cells. Allakos has generated a preclinical pipeline of novel antibodies targeting cell types implicated in allergic and inflammatory responses which it intends to advance to clinical proof-of-concept. Headquartered in the San Francisco Bay Area, Allakos is led by a management team with broad experience in antibody research and development and a strong advisory board of experts in the areas of disease focus.
Applied Genetic Technologies Corporation
Alachua, FL
Applied Genetic Technologies Corporation is a gene therapy company focused on curing genetic defects that cause blindness and other systemic disorders. The Company is developing a pipeline of products that utilize its proprietary, adeno-associated virus (AAV) delivery system and herpes-helper virus production technology.
aTyr Pharma, Inc.
San Diego, CA
aTyr Pharma is a privately held biopharmaceutical company focused on identifying and developing a novel class of naturally occurring protein biologics for human therapeutics.
Cerenis Therapeutics
Toulouse, France and Ann Arbor, MI
Cerenis Therapeutics is a pharmaceutical company focused on the discovery, development and commercialization of HDL-related therapies for the treatment of cardiovascular and metabolic diseases. Based on breakthrough research in HDL therapy, Cerenis is pursuing a range of HDL product candidates that reflect significant commercial opportunities in the treatment of atherosclerosis. The two lead programs are around a synthetic HDL mimetic and a PPAR delta agonist.
Cytokinetics, Inc.
South San Francisco, CA
Cytokinetics is developing novel pharmaceuticals and technologies based on its expertise in cytoskeletal pharmacology and biology. The Company is currently pursuing multiple therapeutic programs in the areas of cancer and cardiovascular diseases. It is in Phase II studies with small molecule therapeutics for solid tumors and for congestive heart failure.
Nasdaq: CYTK
Contact: Farah Champsi
Esperion Therapeutics (spin-out)
Plymouth, MI
Esperion Therapeutics, Inc. discovers and develops therapies to prevent, treat, and reverse cardiovascular and metabolic diseases.
Contact: Dan Janney
Genedata AG
Basel, Switzerland
GeneData develops and commercializes bioinformatics systems and related services in the functional genomics arena. The Company delivers computational solutions for the management and analysis of large quantities of structurally complex biological data, generated by genome sequencing, microarrays, protein expression profiling, metabolic profiling and high-throughput screening.
Immune Design Corp.
Seattle, Washington
Immune Design is a clinical-stage immunotherapy company with next-generation in vivo approaches designed to enable the body’s immune system to fight disease. The Company’s technologies are engineered to activate the immune system’s natural ability to create and/or expand antigen-specific cytotoxic T cells, while enhancing other immune effectors, to fight cancer and other chronic diseases. Immune Design's clinical programs are the product of its two synergistic discovery platforms: ZVexTM and GLAASTM. Immune Design went public in July 2014 and is listed on NASDAQ under the symbol IMDZ.
Contact: Ed Penhoet, Ph.D.
Intarcia Therapeutics, Inc.
Hayward, CA
Intarcia Therapeutics, Inc. is a privately held biopharmaceutical company developing therapies to ensure enhanced treatment outcome by optimizing patient adherence and improving the efficacy, convenience and tolerability of drug therapies. Intarcia's drug development expertise and competitive edge are demonstrated by its abilities to stabilize proteins and peptides at above body temperature and to deliver them in a constant and consistent manner via the proprietary DUROS drug delivery platform. Intarcia is pursuing a clinical stage development program for type 2 diabetes and has other programs for weight regulation to control obesity. The Company’s headquarters and manufacturing facilities are in Hayward, CA.
Kiadis Pharma
Amsterdam, The Netherlands
Kiadis is a private Dutch biopharmaceutical company. Its product pipeline is focused on overcoming limitations and complications of bone marrow transplantation (BMT) procedures for the treatment of end-stage blood cancer patients. The most advanced program, ATIR, is in Phase III multinational registration trial.
Kite Pharma, Inc.
Los Angeles, California
Kite Pharma, Inc. is a privately held development stage biotechnology company engaged in the development of novel cancer immunotherapeutic products with focus on engineered autologous T cell therapy (eACT), designed at restoring the patient's immune system to recognize and eradicate tumors. In partnership with the National Cancer Institute (NCI) Surgery Branch, Kite is advancing a pipeline of proprietary eACT product candidates directed to a wide range of cancer indications. These novel personalized and targeted immunotherapies, which capitalize on the selectivity and potency of immune cells, are aimed at providing significant and durable clinical benefit regardless of tumor origin, disease stage, and prior treatments. In addition, the company is advancing a novel therapeutic cancer vaccine aimed to trigger potent and specific immunity against multiple epithelial cancers, which has the potential to complement its eACT programs.
Contact: Farah Champsi
Neothetics
San Diego, California,
Lithera is a privately held clinical stage developer of pharmaceutical and biomedical products addressing both medical and lifestyle indications in ophthalmology and aesthetic medicine. Lithera’s lead product candidate (LIPO-102) is a novel, injectable pharmaceutical treatment designed to produce local, selective fat tissue reduction (pharmaceutical lipoplasty).
Contact: Dan Janney
Prolacta Bioscience
Monrovia, CA
Prolacta BioScience is a life science company dedicated to the application of science relating to human milk. Prolacta is the pioneer in human milk-based nutritional products for critically-ill and premature infants in the Neonatal Intensive Care Unit. It has created the first and only commercially available Human Milk Fortifier made from 100% human milk, Prolact-Plus™.
Contact: Dan Janney
Scynexis, Inc.
Research Triangle Park, NC
SCYNEXIS is a privately held drug discovery and development company that provides a full range of synthetic chemistry processes and technology to the life sciences industry. In addition to providing development services industry, the Company is also developing a proprietary internal pipeline based on cyclophilin inhibitors, a class of drugs that hold significant potential for a broad range of diseases. The Company has a corporate partnership with Merck to discover and develop anti-fungal and antibacterial anti-infective compounds, as well as an animal health partnership with Merial (a joint venture between Merck and Sanofi-Aventis).
Contact: Ed Penhoet, Ph.D.
Sunesis Pharmaceuticals, Inc.
South San Francisco, CA
Sunesis Pharmaceuticals is a public clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for oncology and other serious diseases. Sunesis has built a broad product candidate portfolio through internal discovery and in-licensing of novel cancer therapeutics. The Company’s most advanced compound, SNS595, has shown promising activity in multiple tumor types including refractory ovarian carcinoma and relapsed/refractory AML.
Nasdaq: SNSS
Sutro Biopharma
Menlo Park, California
Sutro Biopharma is creating opportunities for the development of novel protein-based therapeutics and vaccines using a proprietary cell-free protein synthesis technology. Cell-free technology has the potential to overcome many of the significant limitations associated with using whole mammalian and bacterial cells for making protein-based biologics.
Threshold Pharmaceuticals, Inc.
Redwood City, CA
Threshold Pharmaceuticals is a public biotechnology company focused on the discovery and development of small molecule therapeutics for the treatment of cancer. The Company is developing cancer agents that will take advantage of the lack of oxygen in tumors (hypoxia).
Nasdaq: THLD
Trevena, Inc.
King of Prussia, Pennsylvania
The biased ligand company. Trevena is a privately held biotechnology company focused on discovery and development of the next generation of GPCR targeted medicines. By designing molecules biased towards specific signaling pathways, Trevena aims to unlock new biology and avoid drug side effects. Trevena’s primary therapeutic areas are cardiovascular, pain and inflammation. TRV120027, the lead program in the Trevena portfolio, is an AT1R beta-arrestin biased ligand in Phase 2a studies for acute heart failure.
Contact: Farah Champsi
ViroBay, Inc.
Menlo Park, California
ViroBay is a biotechnology company focused on developing novel HCV protease and polymerase inhibitors.
Contact: Dan Janney